Eliem Therapeutics, Inc.
ELYM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $276,420 | $72,865 | $96,563 | $274,421 |
| - Cash | $87,229 | $93,112 | $43,585 | $46,922 |
| + Debt | $532 | $349 | $480 | $0 |
| Enterprise Value | $189,723 | -$19,898 | $53,458 | $227,499 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$82,020 | -$13,653 | $1,484 | -$35,502 |
| % Margin | – | – | – | – |
| Net Income | -$73,897 | -$35,119 | -$45,353 | -$47,480 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.53 | -1.3 | -1.72 | -1.81 |
| % Growth | -17.7% | 24.4% | 5% | – |
| Operating Cash Flow | -$15,562 | -$20,599 | -$37,369 | -$36,072 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$15,562 | -$20,599 | -$37,369 | -$36,072 |